Nanjing
China
Nanjing Vazyme Biotech Co., Ltd.
SARS-CoV-2, heterologous immunisation, recombinant adenovirus type-5-vectored COVID-19 vaccine, protein-subunit-based COVID-19 vaccine, clinical trial